The humoral IgG immune response against EGFR was investigated in patients with non-small cell lung cancer receiving gefitinib and it was suggested that determining anti-EGFR IgG antibody levels may have prognostic significance (25). Here, EGFR is linked to non-small cell lung carcinoma.